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Abstract
Background: Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by
radiotherapy effecting intracellular signal transduction. With the tyrosine kinase inhibitors new targeted drugs are
available. Imatinib mesylate is a selective inhibitor of bcr-abl, PRGFR alpha, beta and c-kit. The purpose of this study
was to determine whether Imatinib has an influence on the effectiveness of radiotherapy in breast cancer cell lines
and if a combination of imatinib with standard chemotherapy could lead to increased cytoreduction.
Methods: Colony-forming tests of MCF 7 and MDA MB 231 were used to study differences in cell proliferation
under incubation with imatinib and radiation. Changes in expression and phosphorylation of target receptors were
detected using western blot. Cell proliferation, migration and apoptosis assays were performed combining imatinib
with doxorubicin.
Results: The combination of imatinib and radiotherapy showed a significantly stronger inhibition of cell
proliferation compared to single radiotherapy. Differences in PDGFR expression could not be detected, but
receptor phosphorylation was significantly inhibited when treated with imatinib. Combination of imatinib with
standard chemotherapy lead to an additive effect on cell growth inhibition compared to single treatment.
Conclusions: Imatinib treatment combined with radiotherapy leads in breast cancer cell lines to a significant
benefit which might be influenced through inhibition of PDGFR phosphorylation. Combining imatinib with
chemotherapy enhances cytoreductive effects. Further in vivo studies are needed to evaluate the benefit of
Imatinib in combination with radiotherapy and chemotherapy on the treatment of breast cancer.
Background
Breast cancer is the most common malignant tumour in
women. Albeit further increases in incidence, breast
cancer related mortality has been reduced by screening
and early detection programs, as well as optimized ther-
apeutic options. Besides surgery, chemotherapy and
radiotherapy, targeted therapies including endocrine,
small molecule and antibody related therapies have been
able to improve patient outcome [1-5].
In early and advanced breast cancer, radiotherapy is a
common part of standard therapies. External beam
radiotherapy (50 Gy, fraction dose 1.8 - 2 Gy, delivered
over 30 - 35 days) is used for chest wall and total breast
irradiation [6,7].
Radiotherapy targets intracellular DNA and causes
strand breaks. The ability of tumour cells to repair
radiotherapy modulated DNA breaks is limited. Unre-
paired DNA breaks commonly lead to apoptosis, necro-
sis, cell cycle arrest or mitotic inactivity. Radio
sensitivity depends on intrinsic factors, defined by
genetic determination as well as on extrinsic factors like
growth receptor signalling and their chemical or biologi-
cal modulations [8].
Membrane tyrosine kinases play a key role in cell sig-
nalling. Aberrant expression or activation has an impact
on breast cancer oncogenesis and progression. Tyrosine
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any medium, provided the original work is properly cited.kinase inhibitors show activities against one or multiple
targets and are able to inhibit tumour proliferation and
in some cases angiogenesis at the same time [9].
Imatinib mesylate (Glivec®) was originally developed
for tailored inhibition of the oncoprotein bcr-abl in
chronic myeloid leukaemia (CML) and is today part of
CML standard therapies. Besides abl and bcr-abl, imati-
nib also inhibits the activation of PDGFR a, b and c-kit
and is currently used in research and treatment of solid
tumours [10-13].
Cell lines from different solid tumours with c-kit and/
or PDGFR expression have been tested previously for
their response to imatinib. Cell growth of c-kit expres-
sing cell lines of colon and small cell lung cancer could
be inhibited in vitro and in vivo [14]. PDGFR activation
occurs via an autocrine pathway or by ligands. Activa-
tion of PDGFR ß enhances chemotaxis, while cell moti-
lity is decreased after PDGFR a activation. Inhibition of
both subtypes leads to apoptosis. Co-expression of
PDGFR ß and stimulating ligands can be seen in many
malignant lesions [15-19]. Immunohistochemistry
revealed a broad PDGFR expression in breast cancer
[20,21]. Increased expression of PDGF receptors corre-
lates with an increased risk of distant metastasis,
decreased response to chemotherapy and reduced over-
all survival [22,23]. In murine breast tumours inhibition
of activated PDGFR ß by imatinib leads to reduction in
tumour cell growth [20].
Imatinib has also an antiangiogenic effect and leads to
apoptosis in tumour and endothelial cells by blocking
PDGF-B signalling pathways [24-28]. In highly angio-
genic glioblastomas imatinib showed radiosensitizing
activity. Additionally an imatinib related inhibition of
PDGFR b activation leads to a decrease in the interstitial
pressure of solid tumours. This effect promotes an intra-
cellular up-take of substances like cytotoxic agents
[29,30]. Therefore it was suggested to introduce imatinib
into clinical research and therapies of solid tumours like
breast cancer expressing the specific cellular targets.
Expression patterns of tyrosine kinases, relevant for ima-
tinib action, have been described in human breast can-
cer cell lines previously. It is likely, that imatinib action
in solid tumours is related to PDGFR b inhibition [31].
Our hypothesis was that imatinib could contribute to
breast cancer therapy by serving as a potential chemo-
and radiosensitizer.
Methods
Cell Culture
Human breast cancer cell lines (MCF 7 and MDA MB
231) were obtained from American Type Culture Col-
lection, Rockville, USA. Cells were grown in RPMI 1640
medium containing 10% FBS and 1% penicillin/strepto-
mycin at 37°C and 5% CO2. Their tyrosine kinase
receptor and corresponding ligand expression patterns
have been described previously [31].
Ligand dependent proliferation and migration
Cells for proliferation assays were seeded at a density of
10,000 cells/ml on a 96-well plate. After an attaching
period of 24 hours, medium was exchanged for medium
containing only 1% FCS to reduce effects of included
growth factors. Cell lines were incubated either with
PDGF BB (R&D Systems, Minneapolis, MN, USA) (10,
25, 50, 75 or 100 ng/ml) alone or in combination with
imatinib mesylate (IC50 6 μM, defined previously
[31,32]) (generously provided by Novartis, Basel, Swit-
zerland) which was added before application of PDGF
BB. Medium was replaced every 48 hours. After six days
of incubation, experiments were terminated using Cell
Titer Aqueous One Solution Reagent (Promega) and cell
proliferation was measured. For migration assays silicon
spacers were inserted into 12-well plates before cells
were seeded. At the point of cell confluency, spacers
were removed and distances between migration fronts
were measured. Cells were incubated with imatinib,
PDGF BB (25 ng/ml) or their combination for 72 hours
and cell migration was measured every 24 hours using
Axio vision software (Zeiss, Germany). Experiments
were set up in triplicates and performed three times to
confirm results. For statistical analysis student’st - t e s t
was carried out and p-values < 0.05 were declared
significant.
Cell proliferation combining imatinib mesylate and
doxorubicin
Cells were plated on 12-well plates and were allowed to
attach for 24 hours. Then, cells were incubated with
doxorubicin (Sigma-Aldrich, St Louis, MO, USA)
in concentrations of 0.25 nM - 12.5 nM and imatinib
(1.5 - 12 μM) alone and in combinations. Replacement
of medium was carried out every 48 hours and cell pro-
liferation was determined by trypsinization, trypan blue
staining and cell counting after six days. Experiments
were set in triplicates and repeated to confirm results.
Drug interaction was assessed using the combinatory
index, where CI < 1, CI = 1 and CI > 1 indicate syner-
gistic, additive and antagonistic effects. Data analysis
was carried out using the Calcusyn Software (Biosoft,
Oxford, UK)[32,33].
Apoptosis analysis
Breast cancer cell lines were seeded on chamber slides
(MDA MB 231 20,000 cells/ml, MCF 7 40,000 cells/ml)
and after attachment over night, cells were incubated
with imatinib (IC50 6 μM), doxorubicin (1 nM, 2,5 nM
and 5 nM) or the combination of both drugs for 24 and
48 hours. Slides were washed with PBS, cells were fixed
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ried out according to manufacturer’s protocol. Apoptotic
cells were counted in five random fields using fluores-
cence microscopy and expressed as percentage of total
cell number. Student’s t-test was used for statistical ana-
lyses and p-values < 0.05 were declared significant.
Radiation in vitro
Cells were cultured in T 75 cell culture flasks and
seeded at a density of 4,000 (MDA MB 231) and 10,000
(MCF 7) cells/ml. After 24 hours of attaching, cells were
incubated with or without imatinib in concentrations of
4o r6μM. Radiation was performed after another 24
hours using a telecobalt source (Theatron 780C, Phil-
lips) emitting gamma radiation produced by cobalt 60
with energy of 1.33 MeV. In previous experiments a dif-
ference between radiation using cobalt 60 or iridium
192 could not be detected (data not shown). During
radiation and transport, cells were stored in a specially
designed isolated box guaranteeing a constant tempera-
ture of 37°C. A total dose of 10 Gy was applied fractio-
nated in doses of 2 Gy per day on 5 consecutive days.
Cells were counted using the trypan blue method 24
hours after each fraction. All experimental points were
set-up in triplicates and repeated at least twice to con-
firm results.
Colony forming test
Colony forming tests were carried out to detect the
effect of radiation on cell vitality. 1 g of bactoagar (Bec-
ton, Dickinson & Co., Sparks, MD, USA) was boiled in
20 ml pure water and suspended with 20 ml culture
medium. Separately 1,000 MDA MB 231 cells/ml and
3,000 MCF 7 cells/ml were added at 37.5°C. Different
set-ups were used for each dose level. After polymeriza-
tion the agar was covered with 2 ml of cell culture med-
ium. Medium changes took place every seven days and
a f t e r1 0( M D AM B2 3 1 )a n d2 1( M C F7 )d a y so fi n c u -
bation. Colonies consisting of more than 30 cells were
counted. Plating efficiency was calculated by multiplying
t h en u m b e ro fc o l o n i e sb y1 0 0a n dd i v i d i n gi tb yt h e
number of cells plated. To determine the surviving frac-
tion the number of colonies of treated cells was divided
by the number of colonies of non radiated control cells.
Statistical analysis was performed using the student’st -
test and p-values < 0.05 were declared significant.
Immunoblotting
To detect the influence of radiation and imatinib co-
treatment on receptor activation, cells were lysed in lysis
buffer (62.5 mM Tris-HCL (pH 6.8), 2% SDS, 50 mM
DTT and 10% glycerol) and proteinase inhibitor was
added. Protein determination was carried out using the
Bradford method (Bio-Rad, Hercules, CA, USA). 30 μg
of total protein were separated depending on molecular
weight in SDS-PAGE. After transfer onto PVDF-mem-
branes, membranes were blocked and incubated with
primary antibody. Primary antibodies used were rabbit
polyclonal anti-PDGFR b (Santa Cruz Biotechnology,
Santa Cruz, CA), rabbit polyclonal anti-phospho-PDGFR
b (Cell Signalling Technolog y ,D a n v e r s ,M O ,U S A )a n d
anti-b-actin (Sigma-Aldrich). After incubation with cor-
responding secondary horseradish peroxidase-conjugated
antibodies, blots were developed using the ECL-system
(Amersham Biosiences, Piscataway, NJ, USA).
Research reported has been carried out with the
agreement of the ethics committee of the University of
Kiel, Germany (AZ D 426/10).
Results
In previous experiments we could determine that the
cell lines used express receptors which are known imati-
nib targets. All cell lines express PDGFR b and abl.
MCF 7 cells are positive for c-kit and PDGFR a is
expressed by MDA MB 231. Despite their different
expression patterns, imatinib has an anti-proliferative
effect on both breast cancer cell lines with an IC 50
concentration of 6 μM [31,34].
Imatinib inhibits PDGF BB dependent cell proliferation
and migration
In MDA MB 231 cells stimulation with PDGFR b specific
ligand PDGF BB in concentrations of 10 ng/ml leads to
an increased cell growth of 186 percent. Higher ligand
concentrations are not able to induce incremental cell
proliferation (Figure 1). On the other hand imatinib is
able to reduce the proliferative effect of PDGF BB. MCF
7 cells react differently on growth factor application.
PDGF BB induces a cell growth increase of about 20%
among all concentrations used and imatinib is able to
reduce cell proliferation by 50%. The cell growth factor
PDGF BB increases cell growth in breast cancer cell lines.
Response rates to ligand specific signal-transduction vary,
but imatinib is able to exert its anti-proliferative effect on
all breast cancer cells in spite of PDGF BB stimulation.
MDA MB 231 cells show an increase in cell migration
compared to the control upon stimulation with PDGF
BB (Figure 2). Imatinib has the ability to inhibit cell
migration in the absence of PDGF BB and this effect is
also apparent in the presence of growth factor stimula-
tion. In contrast, PDGF BB does not significantly alter
cell migration of MCF 7 breast cancer cells, but imatinib
reduces their migration significantly at 48 hours and as
well at 72 hours of incubation. The tyrosine kinase inhi-
bitor imatinib reduces cell migration of the studied
breast cancer cell lines significantly and this anti-migra-
tory effect persists in the presence of PDGF BB
stimulation.
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enhanced cell growth inhibition
This experiment was set-up to detect if imatinib might
be a useful add-on to the cytotoxic drug doxorubicin
which is used in different therapeutic settings in breast
cancer treatment. Therefore cells were incubated with
increasing concentrations of doxorubicin and imatinib
alone or in combination (Figure 3). Dose ratios were
applied and combination indices were calculated (Table
1). An additive effect on cell proliferation can be
detected in MDA MB 231 cells using a dose ratio of
1:6,000 (doxorubicin:imatinib), which contains the IC50
Figure 1 Imatinib inhibits PDGF BB dependent cell proliferation in breast cancer cell lines. Cells were incubated with increasing
concentrations of PDGF BB and imatinib (IC 50). Cell growth was measured by MTT-assay.
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Page 4 of 14Figure 2 Imatinib inhibits PDGF BB dependent cell migration in breast cancer cells. Migration assays were performed in breast cancer cell
lines. Cells were incubated with either imatinib, PDGF BB or their combination for up to 72 hours. Cell migration was measured and student’st -
test was performed. * indicates p-values < 0.05. Representative images of cell migration after 48 and 72 hours of incubation are displayed.
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reaches an additive effect in higher dose ranges, whereas
the combination of doses lower than the IC50 shows an
antagonistic effect. Both therapeutic drugs show an
additive effect on cell growth inhibition when combined,
which is pronounced in the triple negative MDA MB
231 cell line.
Imatinib’s effect on cell apoptosis
To determine whether the combination of imatinib with
doxorubicin leads to increased levels of cells undergoing
apoptosis, TUNEL assays were carried out. Incubation
of MDA MB 231 cells with imatinib induces apoptosis
in 12 and 10% of cells after 24 and 48 hours. Cells incu-
bated with doxorubicin over the same time show an
apoptotic rate of 5% and 14%. The combination of both
drugs does not increase the level of cells undergoing
apoptosis at these specific time points (Figure 4). In
contrast, apoptotic rates in the hormone receptor posi-
tive MCF 7 cells rise to comparable levels after 24 hours
of incubation with either drug alone or their combina-
tion. Moreover, after 48 hours the amount of apoptotic
cells decreases in imatinib and doxorubicin treated cells
(11% and 15%), whereas the combination shows an
increase in apoptotic cells to 34%. Imatinib and doxoru-
bicin lead to apoptosis induction in both cell lines, but
Figure 3 Combination of imatinib with doxorubicin leads to enhanced cell growth inhibition. Cells were incubated with doxorubicin or
imatinib alone or in combination. Cell proliferation was assessed after six days of incubation. Combination indices were calculated using
Calcusyn software. * = p-value 0.05 determined by student’s t-test.
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be detected when drugs are combined.
Effects of radiation on breast cancer cells
To detect the effect of irradiation on breast cancer cell
lines, the estrogen receptor (ER) positive cell line MCF
7 and the ER negative cell line MDA MB 231 were
selected. Fractionated radiation with 2 Gy per day on 5
following days to reach a total dose of 10 Gy was per-
formed. The surviving fraction of each dose level was
determined. Both cell lines show a decrease in the sur-
viving fraction which correlates with the increasing dose
levels (Figure 5). The decrease is stronger in the highly
proliferative MDA MB 231 cell line.
Combination of imatinib with irradiation reduces breast
cancer cell growth
To evaluate if imatinib could enhance the effect of radia-
tion on breast cancer cells, cells received either single
radiation, imatinib incubation (IC50) or the combination
of both. The surviving fraction was measured after each
dose level (Figure 5). Regarding the surviving fractions of
MDA MB 231 cells, imatinib is able to reduce the surviv-
ing fraction further when combined with irradiation.
These effects can also be seen in the lower proliferating
cell line MCF 7. Here the combined treatment leads to a
decrease of the surviving fraction which is explicitly
detectable after application of higher Gy levels. Com-
pared to each single treatment, the combined application
of irradiation and imatinib further reduces the number of
surviving and colony forming cells.
PDGFR b expression is not effected by irradiation and
imatinib
As the PDGF receptor b is expressed by all cell lines we
decided to further investigate the modulation of this
receptor by imatinib. To detect if changes in PDGFR b
expression occur after imatinib treatment and/or fractio-
nated irradiation, western blot analysis was performed
following different treatment modalities. After each
treatment option, protein lysates were extracted. As
shown in figure 6, the expression of the tyrosine kinase
receptor PDGFR b is not modified by the different treat-
ment options in MCF 7 and MDA MB231 breast cancer
cell lines.
Imatinib causes PDGFR b inactivation in combination with
irradiation
Modulation and inhibition of the PDGFR b signalling
pathway by imatinib can be measured by the receptor
phosphorylation status. Tests were carried out after sin-
gle incubation with imatinib and in combination with
irradiation. MCF 7 cells show an inhibition of receptor
activation when imatinib in a concentration of 6 μMi s
combined with irradiation (Figure 7). An effect of single
imatinib incubation on receptor phosphorylation could
not be detected in this experimental set-up. In contrast
to these results imatinib is able to inhibit PDGFR
b phosphorylation in MDA MB 231 cells. After incuba-
tion with imatinib in concentrations of 4 and 6 μM
receptor activation is blocked. In irradiated breast can-
cer cells this effect on receptor inactivation is consistent.
Discussion
The aim of this study was to detect which effect the tyr-
osine kinase inhibitor imatinib mesylate has on breast
cancer cell lines in vitro when combined with either
chemotherapy or irradiation. Further it was examined
how imatinib modulates the PDGFR b signalling path-
way. For this purpose, expression patterns of imatinib
specific target receptors PDGFR a, b,c - k i ta n dt h e i r
according ligands PDGF A, B and H-SCF-1 were exam-
ined. While PDGFR b was detectable among all cell
lines, PDGFR a was not expressed by MCF 7 cells in
Table 1 Combination indices calculated for imatinib and doxorubicin co-incubations in breast cancer cell lines
MDA MB 231
Drug Combination Index Values at Dm (nM) m r
ED 50 ED 75 ED 90
Combination (1:6000) 1.11214 1.01224 0.99765 0.39732 1.84658 0.96979
Doxorubicin N/A N/A N/A 0.57999 1.15437 0.97662
Imatinib N/A N/A N/A 5581.5821 2.92342 0.99784
MCF 7
Drug Combination Index Values at Dm (nM) m r
ED 50 ED 75 ED 90
Combination (1:1200) 1.32605 1.10981 0.95853 2.03607 1.48647 0.99769
Doxorubicin N/A N/A N/A 4.56443 1.58527 0.96108
Imatinib N/A N/A N/A 7487.20892 1.04304 0.98481
ED 50 (effect dosis 50%), Dm (IC50) calculated, m (measures of sigmoidicity), r (correlation coefficient)
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Page 7 of 14Figure 4 Effect of imatinib and doxorubicin on apoptosis of breast cancer cells. Cells were incubated with imatinib, doxorubicin alone or
their combination for 24 and 48 hours. Apoptotic fraction was estimated by TUNEL assay and apoptotic cells were counted using fluorescence
microscopy. For each sample, a total of five times 200-500 cells were scored and apoptotic fractions are expressed as percentage of total cells
counted. Apoptotic cells show a green nuclear staining compared to vital cells.
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Page 8 of 14this setting, but they were positive for c-kit. The ligands
PDGF A and B were transcribed by both cell lines and
H-SCF-1 only by MCF 7. These expression patterns cor-
respond with other studies which describe an expression
of the ligand PDGF A but not the PDGFR a receptor by
MCF 7 cells [35]. So far only few groups have
performed immunohistochemical analysis in primary
breast cancers on PDGFR expression which plays an
important role in autocrine and paracrine stimulation of
cancer and stromal cells as well as in angiogenesis [13].
An expression of PDGFR a could be detected in 40% of
ductal invasive breast cancers and more than 80% of
Figure 5 Combination of imatinib with irradiation reduces breast cancer cell growth in vitro. Cells were incubated with imatinib alone,
received irradiation of 2 Gy per day for 5 days or the combination of both. Colony-forming tests were performed and the surviving fraction was
calculated dividing the number of colonies of treated cells by the number of colonies of non radiated control cells. Representative colonies of
MCF 7 cells are shown.
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relation between receptor expression and axillary lymph
node metastasis has been suggested [35]. PDGFR b is
expressed in endothelial cells of ductal carcinoma in situ
[36] and also of prognostic value in peritumoral stroma
[37]. Positivity has been reported for over 50% of inva-
sive carcinoma cells.
Furthermore, autocrine stimulation of PDGF receptors
is reported as an important factor in tumor progression
and metastasis [38,39]. Likewise poor overall survival
rates and low response to chemotherapy are correlated
with over-expression of PDGF receptors [23]. Therefore
by targeting these receptors, imatinib might be able to
inhibit local tumour growth and decrease metastatic
potential.
In previous studies we were able to determine a cell
growth inhibition of imatinib on breast cancer cell lines
in clinically relevant concentrations of 4 to 6 μMw h i c h
could be confirmed by other groups [31,34]. In other
cancer entities such as pancreatic cancer or medullary
cancer of the thyroid gland higher concentrations were
needed to cause cell growth inhibition in vitro which
might be due to different receptor expression patterns
[40,41]. Oral application of 25-600 mg imatinib can lead
to plasma levels of about 0.17-5.68 μMi nv i v o[ 4 2 ] .
Therefore in vivo effects of imatinib in breast cancer
patients appear to be reasonable in a tolerable dose.
To further investigate the interaction of imatinib with
growth signalling pathways, we have chosen the PDGFR
b axis because this receptor is expressed among both
cell lines examined. Moreover it is not sure if c-kit acti-
vation mediates cell proliferation in breast cancer
[14,43]. At least we were not able to detect an increased
cell growth through SCF (c-kit ligand) application in
previous experiments, whereas incubation with PDGF
BB leads to augmented cell growth in all breast cancer
cell lines and has the ability to stimulate cell migration.
Similar results could be detected by other research
groups who could show that PDGF BB application leads
to increased cell growth whereas PDGF AA had no
Figure 6 PDGFR b expression is not effected by irradiation and imatinib. Breast cancer cell lines underwent irradiation, incubation with
imatinib or the combination of both. Total protein was extracted and western blot was carried out using antibodies against PDGFR b.
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and breast cancer cell lines an inhibition of PDGF BB
generated PDGFR b phosphorylation could be detected
after imatinib incubation [19,27,31].
PDGFR b activation is known to cause a protective
effect against the antiproliferative potential of che-
motherapeutic drugs as paclitaxel and doxorubicin in
various cancer entities [28,45]. For this reason, the effect
of a combination of imatinib, as a PDGFR b inhibitor,
with chemotherapeutic drugs in breast cancer cells
appeared to be promising. In previous experiments we
could determine a significant cell growth inhibition
when imatinib was combined with vinorelbine compared
to a single vinorelbine treatment [31]. Moreover a com-
bination of imatinib with cisplatin has an additive effect
on cell growth inhibition [46]. In this experimental set-
ting we studied the effect of imatinib in combination
with doxorubicin, which is frequently used in the adju-
vant and palliative therapy of breast cancer.
In combination with doxorubicin an increase in che-
mosensitivity due to the potential of imatinib to inhibit
PDGFR b could be demonstrated among feline vaccine-
associated sarcomas [47]. In this experimental setting
we were able to prove that imatinib, despite its potential
of decreasing the interstitial pressure in tumours and
enhancing anti-angiogenic effects in vivo, is able to alter
the chemosensitivity of breast cancer cell lines in vitro.
This is of major interest because clinical trials investi-
gating the effect of imatinib either as a monotherapy or
combined with docetaxel in metastasized breast cancer
do not show significant results even if patients were
selected according to PDGF receptor expression of
tumour cells [48-50]. For this reason, it is important to
perform further trials combining imatinib with che-
motherapeutic drugs. A selection of patients expressing
targets for imatinib treatment is of great relevance.
Irradiation is an important component of standard
therapy in the adjuvant as well as in the metastasized
setting of breast cancer. For this reason, we investigated
the effect of irradiation and the combination with imati-
nib on breast cancer cell lines in vitro. Comparing the
two breast cancer cell lines MCF 7 and MDA MB 231,
t h e r ei ss o m ei n h o m o g e n i t yi nt h ea n t i - p r o l i f e r a t i v e
effect caused by ionizing radiation. MDA MB 231 has a
higher mitotic potential and therefore a higher plating
efficiency compared to MCF 7. Moreover, the surviving
fraction of MDA MB 231 compared to MCF 7 cells
according to the radiation doses is diminished in the
cell colony forming test. The demonstrated differences
in radiosensitivity of both breast cancer cell lines corre-
late with formerly published results for unfractionated
irradiation [51,52]. To investigate the effect of imatinib
on radiosensitivity of breast cancer cell lines, cells were
incubated with imatinib and a fractionated radiation was
applied. Comparing the surviving fractions of cells
undergoing radiation only or imatinib incubation only
with the combination of both demonstrates that the
combination treatment leads to a further decrease in
Figure 7 Imatinib causes PDGFR b inactivation in combination with irradiation. Cell lines were treated with imatinib alone or in
combination with irradiation. Total protein was extracted and western blot analysis was carried out using antibodies against phospho-PDGFR b.
Equal loading was confirmed by b-Actin detection.
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able among all dose levels of radiation. These results are
similar to other investigations on radiosensitivity modu-
lation through imatinib in different cancer cell lines in
vitro [20,53-55]. The effect of a combination of imati-
nib and radiation was studied in particular in glioblas-
tomas. Incubation with imatinib increases the
radiosensitivity in glioblastoma cell lines whereas there
is no detectable alteration among fibroblasts [56-58].
The effectivity of this combinatory treatment can not
yet fully be explained. A possible explication might be
an inhibition of the PDGF receptor pathway by imati-
nib, which interacts with the alterations of cell signal-
ling, caused by radiation. By inhibiting the PDGF
receptor signalling, there might occur a blockade of
cell repair mechanisms which are important in repair-
ing radiation induced damages like double-strand
breaks on the DNA level. In PDGFR expressing glio-
blastoma cells the addition of imatinib to irradiation
induced a significant increase of cells undergoing
apoptosis. The effect of radiation could be improved
through imatinib enhanced apoptosis rates [53].
As well as for chemotherapy, a high interstitial fluid
pressure (IFP) is also a prognostic marker for poor
response on irradiation [59]. For this reason a dimin-
ished IFP due to imatinib mediated PDGFR inhibition
could be another mechanism to alter the effects of irra-
diation. We could show that there is no change in
PDGFR b expression when cells were incubated with
single imatinib or in combination with radiation. Single
irradiation has no effect on receptor activation whereas
combination with imatinib leads to an inhibition of
receptor phosphorylation in both cell lines. This effect
was formerly described in other cancer entities like glio-
blastomas, ovarian cancer and small cell lung cancer
[10,19,60]. According to our results, single radiation
does not cause any changes in PDGFR b activity in glio-
blastoma cells, whereas a direct correlation between
imatinib induced inhibition of PDGFR b phosphoryla-
tion and increased radiosensitivity was detected [57].
Imatinib is able to modify several different cell signalling
pathways and has therefore diverse possibilities in mod-
ulating the effects of irradiation. It is certain that inhibi-
tion of the PDGFR b p a t h w a yp l a y sad e c i s i v er o l ei n
the enhancement of radiosensitivity in breast cancer cell
lines.
Conclusions
I m a t i n i ba sat y r o s i n ek i n a s ei n h i b i t o rh a st h ea b i l i t yt o
modulate receptor pathways. In our study we could
demonstrate that imatinib is able to inhibit the auto-
crine and paracrine mediated activation of the PDGFR b
pathway and therefore to inhibit the PDGF BB induced
proliferation as well as migration of breast cancer cell
lines in vitro. In combination with the chemotherapeutic
drug doxorubicin, an additive effect on the inhibition of
cell proliferation could be detected. If combined with
fractionated radiotherapy a decrease in the surviving
fraction of breast cancer cells compared to single treat-
ment is caused by imatinib. A possible explanation for
this enhanced radio- and chemosensitivity seams to be
the imatinib mediated inhibition of the PDGFR b
pathway.
Further clinical trials have to be performed to approve
these effects on breast cancer in vivo. A strong selection
of patients expressing targets for imatinib is required to
survey the influence of imatinb in combination with
radiation or chemotherapy in breast cancer patients.
Overall the results of this study suggest imatinib to be a
candidate as an effective add-on in breast cancer related
chemo- and radiotherapy. For this reason, imatinib
remains a promising drug in the treatment of breast
cancer.
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